Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: Results from the IRIS study Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Leukemia, Myeloid, Chronic-Phase
  • Piperazines
  • Pyrimidines
  • Quality of Life

abstract

  • Imatinib offers clear QOL advantages compared with IFN+LDAC as first-line treatment of chronic phase CML. In addition, patients who cross over to imatinib from IFN+LDAC experience a significant improvement in QOL compared with patients who continue to take IFN+LDAC.

publication date

  • June 2003

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2003.12.154

PubMed ID

  • 12775739

Additional Document Info

start page

  • 2138

end page

  • 46

volume

  • 21

number

  • 11